Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 16/20 | 0.57 |
| ▸ | PPARA | Q07869 | 14/20 | 0.57 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812183 | 0.93 | PPARD (0.58) | PPARDPPARAPPARGMAPTALDH1A1 | |
| SCHEMBL5412181 | 0.93 | PPARD (0.53) | PPARDPPARAPPARGMAPTSMN1; SMN2 | |
| SCHEMBL4809878 | 0.93 | PPARD (0.56) | PPARDPPARAPPARGMAPTALDH1A1 | |
| SCHEMBL4809798 | 0.92 | PPARD (0.56) | PPARDPPARAPPARGMAPTSMN1; SMN2 | |
| SCHEMBL4802196 | 0.92 | PPARD (0.57) | PPARDPPARAPPARGMGLL | |
| SCHEMBL4809165 | 0.91 | PPARD (0.53) | PPARDPPARAPPARGMAPTALDH1A1 | |
| SCHEMBL4803226 | 0.90 | PPARD (0.51) | PPARDPPARAPPARGMAPTSMN1; SMN2 | |
| SCHEMBL4809114 | 0.90 | PPARD (0.60) | PPARDPPARAPPARGMAPTALDH1A1 | |
| SCHEMBL4810994 | 0.89 | PPARD (0.61) | PPARDPPARAPPARGMAPTALDH1A1 | |
| SCHEMBL5474227 | 0.88 | PPARD (0.60) | PPARDPPARAPPARGMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449468-B2 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070225294-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | BANKER PIERETTE | 2007-09-27 | — | — | US | disclosed |
| US-20070072871-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | BANKER PIERETTE | 2007-03-29 | — | — | US | disclosed |
| EP-1349843-B1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | SMITHKLINE BEECHAM CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20040072838-A1 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072871-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | PPARD, PPARG, PPARA | PPARD 1/4885PPARA 3/4885PPARG 2/4885 |
| US-20070225294-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GPR119, PPARA, PPARG | PPARD 4/4885PPARA 2/4885PPARG 3/4885 |
| US-20040072838-A1 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.